Clinical Trials for Metaplastic Breast Cancer

[[["Approval Dates","Location","Type","Phase","Criteria\/Contacts"],["6\/2016 to 12\/2020",null,"ARQ 751 in Solid Tumors with AKT1, 2, <br>3 Genetic Alterations, Activating PI3K Mutations, PTEN-null, <br>or Other Known Actionable PTEN Mutations","Phase 1","<a href='https:\/\/www.arqule.com\/pipeline\/arq-751\/?fbclid=IwAR0QCtkVV2wkoNWp1sMQ5zkLHDs1vQcw_yhsEmUdo_x-T77vJt_qDkWyoO4'>Link<\/a>"],["1\/13\/17 to 8\/31\/2020","<a href='https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02834013?show_locs=Y#locn'>LOCATIONS<\/a>","DART: DUAL ANTI-CLA-4 AND ANTI- PD1 BLOCKADE IN RARE TUMORS- <br>INTERVENTIONAL",null,"<a href=\"https:\/\/faculty.mdanderson.org\/profiles\/filip_janku.html\">Link<\/a><br><a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02834013\">Link<\/a><br><a href=\"https:\/\/swog.org\/Visitors\/Fall17GpMtg\/DART.pdf\">Link<\/a><br><a href=\"http:\/\/swog.org\/Visitors\/ViewProtocolDetails.asp?ProtocolID=2318\">Link<\/a>"],["11\/2015 to 11\/2020","UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER- <br>HOUSTON, TX ","ARTEMIS TRIAL-<br> INTERVENTIONAL",null,"<a href=\"https:\/\/www.mdanderson.org\/patients-family\/diagnosis-treatment\/clinical-trials\/clinical-trials-index\/clinical-trials-detail.ID2014-0185.html\">Link<\/a><br><a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02276443\">Link<\/a>"],["10\/4\/2016 to 3\/14\/2017","NYU LANGONE MEDICAL CENTER- \nNY, NY","IMMUNOTHERAPY COMBO- \nPEMBROLIZUMAB & NABPACLITAXEL","Phase 2","<a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02752685?term=Pembrolizumab%20and%20Nabpaclitaxel&rank=1\">Link<\/a>"],["7\/2016 to 8\/2019","HOUSTON METHODIST HOSPITAL <br> HOUSTON, TX","IMMUNOTHERAPY COMBO- \nL-NMMA PLUS DOCETAXEL","Phase 1B","<a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02834403?term=LNMMA&rank=2\">Link<\/a>"],["1\/2016-1\/2019","UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER- <br>HOUSTON, TX ","TARGETED THERAPY","Phase 2","<a href='https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02456857'>Link<\/a>"]],[{"row":0,"col":0,"visualRow":0,"visualCol":0,"prop":0,"borders":{"className":"border_row0col0","border":{"width":1,"color":"#000","cornerVisible":false},"row":0,"col":0,"top":{"hide":true},"right":{"hide":true},"bottom":{"hide":true},"left":{"hide":true}},"jtcellstyle":{"font-weight":"bold"}},{"row":0,"col":1,"visualRow":0,"visualCol":1,"prop":1,"jtcellstyle":{"font-weight":"bold"}},{"row":0,"col":2,"visualRow":0,"visualCol":2,"prop":2,"jtcellstyle":{"font-weight":"bold"}},{"row":0,"col":3,"visualRow":0,"visualCol":3,"prop":3,"jtcellstyle":{"font-weight":"bold"}},{"row":0,"col":4,"visualRow":0,"visualCol":4,"prop":4,"jtcellstyle":{"font-weight":"bold"}},{"row":1,"col":0,"visualRow":1,"visualCol":0,"prop":0},{"row":1,"col":1,"visualRow":1,"visualCol":1,"prop":1},{"row":1,"col":2,"visualRow":1,"visualCol":2,"prop":2},{"row":1,"col":3,"visualRow":1,"visualCol":3,"prop":3},{"row":1,"col":4,"visualRow":1,"visualCol":4,"prop":4},{"row":2,"col":0,"visualRow":2,"visualCol":0,"prop":0},{"row":2,"col":1,"visualRow":2,"visualCol":1,"prop":1},{"row":2,"col":2,"visualRow":2,"visualCol":2,"prop":2},{"row":2,"col":3,"visualRow":2,"visualCol":3,"prop":3},{"row":2,"col":4,"visualRow":2,"visualCol":4,"prop":4},{"row":3,"col":0,"visualRow":3,"visualCol":0,"prop":0},{"row":3,"col":1,"visualRow":3,"visualCol":1,"prop":1},{"row":3,"col":2,"visualRow":3,"visualCol":2,"prop":2},{"row":3,"col":3,"visualRow":3,"visualCol":3,"prop":3},{"row":3,"col":4,"visualRow":3,"visualCol":4,"prop":4},{"row":4,"col":0,"visualRow":4,"visualCol":0,"prop":0},{"row":4,"col":1,"visualRow":4,"visualCol":1,"prop":1},{"row":4,"col":2,"visualRow":4,"visualCol":2,"prop":2},{"row":4,"col":3,"visualRow":4,"visualCol":3,"prop":3},{"row":4,"col":4,"visualRow":4,"visualCol":4,"prop":4},{"row":5,"col":0,"visualRow":5,"visualCol":0,"prop":0},{"row":5,"col":1,"visualRow":5,"visualCol":1,"prop":1},{"row":5,"col":2,"visualRow":5,"visualCol":2,"prop":2},{"row":5,"col":3,"visualRow":5,"visualCol":3,"prop":3},{"row":5,"col":4,"visualRow":5,"visualCol":4,"prop":4},{"row":6,"col":0,"visualRow":6,"visualCol":0,"prop":0},{"row":6,"col":1,"visualRow":6,"visualCol":1,"prop":1},{"row":6,"col":2,"visualRow":6,"visualCol":2,"prop":2},{"row":6,"col":3,"visualRow":6,"visualCol":3,"prop":3},{"row":6,"col":4,"visualRow":6,"visualCol":4,"prop":4}],[{"row":0,"col":0,"top":{"hide":true},"right":{"hide":true},"bottom":{"hide":true},"left":{"hide":true},"border":{"width":1,"color":"#000","cornerVisible":false}}],[]][]

Approval Dates	Location	Type	Phase	Criteria/Contacts
Approval Dates: 6/2016 to 12/2020	Location:	Type: ARQ 751 in Solid Tumors with AKT1, 2, 3 Genetic Alterations, Activating PI3K Mutations, PTEN-null, or Other Known Actionable PTEN Mutations	Phase: Phase 1	Criteria/Contacts: Link
Approval Dates: 1/13/17 to 8/31/2020	Location: LOCATIONS	Type: DART: DUAL ANTI-CLA-4 AND ANTI- PD1 BLOCKADE IN RARE TUMORS- INTERVENTIONAL	Phase:	Criteria/Contacts: Link Link Link Link
Approval Dates: 11/2015 to 11/2020	Location: UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER- HOUSTON, TX	Type: ARTEMIS TRIAL- INTERVENTIONAL	Phase:	Criteria/Contacts: Link Link
Approval Dates: 10/4/2016 to 3/14/2017	Location: NYU LANGONE MEDICAL CENTER- NY, NY	Type: IMMUNOTHERAPY COMBO- PEMBROLIZUMAB & NABPACLITAXEL	Phase: Phase 2	Criteria/Contacts: Link
Approval Dates: 7/2016 to 8/2019	Location: HOUSTON METHODIST HOSPITAL HOUSTON, TX	Type: IMMUNOTHERAPY COMBO- L-NMMA PLUS DOCETAXEL	Phase: Phase 1B	Criteria/Contacts: Link
Approval Dates: 1/2016-1/2019	Location: UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER- HOUSTON, TX	Type: TARGETED THERAPY	Phase: Phase 2	Criteria/Contacts: Link